CD20 Protein (AA 1-297) (His tag)
-
- Target See all CD20 (MS4A1) Proteins
- CD20 (MS4A1) (Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1))
- Protein Type
- Recombinant
- Biological Activity
- Active
- Protein Characteristics
- AA 1-297
-
Origin
- Human
-
Source
- HEK-293 Cells
- Purification tag / Conjugate
- This CD20 protein is labelled with His tag.
- Sequence
- AA 1-297
- Purity
- >85 % as determined by SDS-PAGE.
- Endotoxin Level
- Less than 1.0 EU per μg by the LAL method.
- Top Product
- Discover our top product MS4A1 Protein
-
-
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH 7.5
- Handling Advice
- Please avoid repeated freeze-thaw cycles.
- Storage
- -80 °C
-
- Target
- CD20 (MS4A1) (Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1))
- Alternative Name
- CD20 (MS4A1 Products)
- Synonyms
- B1 Protein, Bp35 Protein, CD20 Protein, CVID5 Protein, LEU-16 Protein, MS4A2 Protein, S7 Protein, AA960661 Protein, Cd20 Protein, Ly-44 Protein, Ms4a2 Protein, MS4A1 Protein, bp35 Protein, cd20 Protein, ms4a2 Protein, leu-16 Protein, ms4a4c Protein, cd20-like Protein, membrane spanning 4-domains A1 Protein, membrane-spanning 4-domains, subfamily A, member 1 Protein, B-lymphocyte antigen CD20 Protein, MS4A1 Protein, Ms4a1 Protein, ms4a1 Protein, LOC101694281 Protein
- Background
- B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last, it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5), also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
- Molecular Weight
- 35.2 kDa
- NCBI Accession
- NP_068769
-